Hepatic Encephalopathy Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies – Rifaximin (SSD), AXA1665, GR3027 (Golexanolone), VE303

The Hepatic Encephalopathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hepatic Encephalopathy pipeline products will significantly revolutionize the Hepatic Encephalopathy market dynamics.  

Hepatic Encephalopathy Overview

Hepatic encephalopathy (HE) is a brain disorder that develops in some individuals with liver disease. HE presents as a spectrum of neuropsychiatric symptoms ranging from subtle fluctuating cognitive impairment to coma and is a significant contributor to morbidity in patients with liver disease. It is observed in acute liver failure, liver bypass procedures – for example, shunt surgery and trans-jugular intrahepatic Portosystemic shunt – and cirrhosis, classified as Type A, B, and CHE, respectively. Pathogenesis is linked with ammonia and glutamine production. 

Some of the key facts of the Hepatic Encephalopathy Market Report: 

• The Hepatic Encephalopathy market size was estimated at USD 1,563 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Hepatic Encephalopathy cases in the 7MM are increasing mainly due to increased awareness, increased healthcare concerns, longer life expectancy as well as changes in cirrhosis admission
• Total diagnosed prevalent cases of Cirrhosis (hospitalized) in the 7MM was found to be 862,508 cases in 2021. These cases are expected to increase by 2032 
• Among 7MM, the United States has the highest diagnosed prevalent cases of hepatic encephalopathy with 205,664 cases in 2021 
• The United States accounts for the largest market size of Hepatic Encephalopathy, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. 
• Key Hepatic Encephalopathy Companies: Salix Pharmaceuticals, Bausch Health, Axcella Health, Umecrine Cognition, Vedanta Biosciences, and others 
• Key Hepatic Encephalopathy Therapies: Rifaximin (SSD), AXA1665, GR3027 (Golexanolone), VE303, and others 
• The Hepatic Encephalopathy epidemiology based on gender analyzed that out of the total diagnosed prevalent cases of Hepatic Encephalopathy, in the United States, 72.70% were occupied by males

Get a Free sample for the Hepatic Encephalopathy Market Report

Key benefits of the Hepatic Encephalopathy Market report:

1. Hepatic Encephalopathy market report covers a descriptive overview and comprehensive insight of the Hepatic Encephalopathy Epidemiology and Hepatic Encephalopathy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Hepatic Encephalopathy market report provides insights on the current and emerging therapies.
3. Hepatic Encephalopathy market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Hepatic Encephalopathy market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Hepatic Encephalopathy market.

Discover more about therapies set to grab major Hepatic Encephalopathy market share @ Hepatic Encephalopathy market forecast 

Hepatic Encephalopathy Epidemiology Segmentation:

The Hepatic Encephalopathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Hepatic Encephalopathy
• Prevalent Cases of Hepatic Encephalopathy by severity
• Gender-specific Prevalence of Hepatic Encephalopathy
• Diagnosed Cases of Episodic and Chronic Hepatic Encephalopathy 

Hepatic Encephalopathy Market  

The dynamics of the Hepatic Encephalopathy market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Golexanolone (GR3027) for Covert Hepatic Encephalopathy and Rifaximin (SSD) for Overt Hepatic Encephalopathy, and others during the forecasted period 2019-2032. 

Download the report to understand which factors are driving Hepatic Encephalopathy epidemiology trends @ Hepatic Encephalopathy Epidemiological Insights 

Hepatic Encephalopathy Market Drivers

• Increasing diagnosed prevalence of Hepatic Encephalopathy
• Emergence in novel Hepatic Encephalopathy treatment target
• Less competition among therapies

Hepatic Encephalopathy Therapies and Key Companies

• Rifaximin (SSD): Salix Pharmaceuticals/Bausch Health
• AXA1665: Axcella Health
• GR3027 (Golexanolone): UmecrineCognition
• VE303: Vedanta Biosciences

Scope of the Hepatic Encephalopathy Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hepatic Encephalopathy Companies: Salix Pharmaceuticals, Bausch Health, Axcella Health, Umecrine Cognition, Vedanta Biosciences, and others
• Key Hepatic Encephalopathy Therapies: Rifaximin (SSD), AXA1665, GR3027 (Golexanolone), VE303, and others
• Hepatic Encephalopathy Therapeutic Assessment: Hepatic Encephalopathy current marketed and Hepatic Encephalopathy emerging therapies
• Hepatic Encephalopathy Market Dynamics:  Hepatic Encephalopathy market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Hepatic Encephalopathy  Market Access and Reimbursement 

Hepatic Encephalopathy Market Barriers

• Adverse events associated with the current therapies
• The pipeline not very robust
• Disease burden
• Challenges in the diagnosis of disease

Table of Contents 

1. Hepatic Encephalopathy Market Report Introduction

2. Executive Summary for Hepatic Encephalopathy

3. SWOT analysis of Hepatic Encephalopathy

4. Hepatic Encephalopathy Patient Share (%) Overview at a Glance

5. Hepatic Encephalopathy Market Overview at a Glance

6. Hepatic Encephalopathy Disease Background and Overview

7. Hepatic Encephalopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Hepatic Encephalopathy 

9. Hepatic Encephalopathy Current Treatment and Medical Practices

10. Hepatic Encephalopathy Unmet Needs

11. Hepatic Encephalopathy Emerging Therapies

12. Hepatic Encephalopathy Market Outlook

13. Country-Wise Hepatic Encephalopathy Market Analysis (2019–2032)

14. Hepatic Encephalopathy Market Access and Reimbursement of Therapies

15. Hepatic Encephalopathy Market drivers

16. Hepatic Encephalopathy Market barriers

17.  Hepatic Encephalopathy Appendix

18. Hepatic Encephalopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Hepatic Encephalopathy treatment, visit @ Hepatic Encephalopathy Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/